Investigational Drug Information for Basmisanil
What is the drug development status for Basmisanil?
Basmisanil is an investigational drug.
There have been 4 clinical trials for Basmisanil.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 30th 2016.
The most common disease conditions in clinical trials are Cognition Disorders, Stroke, and Ischemic Stroke. The leading clinical trial sponsors are Hoffmann-La Roche and [disabled in preview].
There are zero US patents protecting this investigational drug and zero international patents.
Summary for Basmisanil
| US Patents | 1,487 |
| International Patents | 7,027 |
| US Patent Applications | 2,961 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 2,970 |
| Clinical Trial Progress | Phase 2 (2016-11-30) |
| Vendors | 54 |
Recent Clinical Trials for Basmisanil
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children With Dup15q Syndrome | Hoffmann-La Roche | Phase 2 |
| A Study to Evaluate the Safety and Efficacy of Basmisanil in Adults With Severe Motor Impairment Following an Ischemic Stroke | Hoffmann-La Roche | Phase 2 |
| A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics | Hoffmann-La Roche | Phase 2 |
Clinical Trial Summary for Basmisanil
Top disease conditions for Basmisanil
Top clinical trial sponsors for Basmisanil
US Patents for Basmisanil
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Basmisanil | ⤷ Start Trial | Bisarylsulfonamides useful in the treatment of inflammation and cancer | Kancera AB | ⤷ Start Trial |
| Basmisanil | ⤷ Start Trial | Polycyclic compounds as lysophosphatidic acid receptor antagonists | Amira Pharmaceuticals Inc | ⤷ Start Trial |
| Basmisanil | ⤷ Start Trial | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors | Incyte Corp , Incyte Holdings Corp | ⤷ Start Trial |
| Basmisanil | ⤷ Start Trial | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | Novartis AG | ⤷ Start Trial |
| Basmisanil | ⤷ Start Trial | Substituted indole Mcl-1 inhibitors | Vanderbilt University (Nashville, TN) | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Basmisanil
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Basmisanil | Australia | AU2012356738 | 2031-12-22 | ⤷ Start Trial |
| Basmisanil | Brazil | BR112014015607 | 2031-12-22 | ⤷ Start Trial |
| Basmisanil | Canada | CA2859586 | 2031-12-22 | ⤷ Start Trial |
| Basmisanil | China | CN104168958 | 2031-12-22 | ⤷ Start Trial |
| Basmisanil | European Patent Office | EP2794009 | 2031-12-22 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
